Methamphetamine is known to produce pupil dilation, a physical effect. A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to dramatic saucer-like expansion where the dark pupil dominates the iris. This effect is one of the most recognizable signs of psychedelic and stimulant intoxication and directly contributes to light sensitivity, enhanced color perception, and the characteristic "wide-eyed" appearance.
Pupil dilation, clinically termed mydriasis, is experienced as an expansion of the dark pupil opening that allows significantly more light to enter the eye. The user may first notice the effect by catching their reflection—the pupils appear conspicuously large, with the colored iris reduced to a thin ring around vast dark circles. Functionally, the world appears brighter and more vivid, colors seem more saturated, and light sources take on a more intense, sometimes halo-like quality. In dim environments, the enhanced light sensitivity can feel pleasant and immersive. In bright environments, however, the dilated pupils admit uncomfortably excessive light, producing squinting, eye watering, and photophobia.
The degree of dilation follows a dose-dependent curve. At threshold doses, pupils may be slightly wider than normal—perhaps 5-6mm instead of the typical 3-5mm resting diameter—noticeable only upon close inspection. At moderate doses, dilation to 6-7mm becomes obvious to casual observers, and the person's eyes take on a distinctly alert, wide-open quality. At strong doses, dilation to 7-9mm creates the characteristic "saucer eyes" where the pupil dominates the iris, and the reflex constriction to bright light is noticeably sluggish. At extreme levels, the pupil may be maximally dilated at 8-9mm with virtually no visible iris, and the pupillary light reflex is severely blunted or absent.
Several factors influence the character and duration of mydriasis. Psychedelic mydriasis (LSD, psilocybin, mescaline) tends to be sustained throughout the experience and is bilateral and symmetric. It often co-occurs with enhanced color perception and visual effects. Stimulant mydriasis (amphetamines, cocaine, MDMA) tends to be more variable, fluctuating with sympathetic nervous system arousal. Anticholinergic mydriasis (diphenhydramine, scopolamine, atropine) produces the most extreme and prolonged dilation, sometimes persisting for 24-72 hours, and is accompanied by near-total loss of the pupillary light reflex and paralysis of accommodation (difficulty focusing on near objects).
The pharmacological mechanism involves disruption of the sympathetic-parasympathetic balance governing pupil size. Under normal conditions, the pupillary sphincter (constriction) is controlled by parasympathetic muscarinic innervation, while the pupillary dilator is controlled by sympathetic adrenergic innervation. Substances that increase sympathetic tone (stimulants, via norepinephrine release) activate the dilator muscle. Substances that block parasympathetic activity (anticholinergics) release the sphincter from tonic constriction. Serotonergic psychedelics produce mydriasis through 5-HT2A receptor-mediated inhibition of the Edinger-Westphal nucleus, reducing parasympathetic input to the sphincter.
Mydriasis is most commonly produced by psychedelics (LSD, psilocybin, DMT, mescaline), stimulants (MDMA, amphetamines, cocaine), anticholinergic compounds, and to a lesser degree by cannabis and some dissociatives. It is one of the most universally reliable indicators of psychedelic or stimulant intoxication and is often the first thing noticed by sober observers. Duration varies dramatically: stimulant mydriasis typically resolves within hours, psychedelic mydriasis can persist for 6-12+ hours with LSD, and anticholinergic mydriasis may last days.
While not inherently dangerous, dilated pupils create functional visual impairment in bright environments and significantly increase susceptibility to UV retinal damage. Users should wear UV-protective sunglasses outdoors during mydriasis. Driving is impaired by the altered light response and should be avoided. In social contexts, dilated pupils are a conspicuous marker of intoxication that may draw unwanted attention. If unilateral mydriasis occurs (one pupil dilated, the other normal), this is not typically substance-related and may indicate a neurological emergency requiring immediate medical evaluation.
Pupil dilation can manifest at varying intensities depending on the dose of Methamphetamine and individual sensitivity. The following levels describe the typical progression of this effect.
Subtle widening of pupils to approximately 5-6mm. Only noticeable upon close inspection. Slight enhancement of brightness perception.
Clearly dilated pupils at 6-7mm. Observers may comment on the person's 'wide eyes.' Colors appear slightly more vivid. Mild photosensitivity in bright light.
Prominently dilated pupils at 7-8mm. The dark pupil clearly dominates the iris. Photophobia in bright environments. Sluggish pupillary light reflex.
Very large pupils at 8-9mm with the iris reduced to a thin ring. Significant light sensitivity. Near-absence of light reflex. The characteristic 'saucer-eyed' appearance.
Maximum dilation with virtually no visible iris. Complete loss of pupillary light reflex. Extreme photophobia. Vision may be blurry due to loss of depth of field. Often seen with anticholinergics.
Pharmacodynamics
Methamphetamine has been identified as a potent full agonist of trace amine-associated receptor 1 (TAAR1), a G protein-coupled receptor (GPCR) that regulates brain catecholamine systems. Activation of TAAR1 increases cyclic adenosine monophosphate (cAMP) production and either completely inhibits or reverses the transport direction of the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). When methamphetamine binds to TAAR1, it triggers transporter phosphorylation via protein kinase A (PKA) and protein kinase C (PKC) signaling, ultimately resulting in the internalization or reverse function of monoamine transporters. Methamphetamine is also known to increase intracellular calcium, an effect which is associated with DAT phosphorylation through a Ca2+/calmodulin-dependent protein kinase (CAMK)-dependent signaling pathway, in turn producing dopamine efflux. TAAR1 has been shown to reduce the firing rate of neurons through direct activation of G protein-coupled inwardly-rectifying potassium channels. TAAR1 activation by methamphetamine in astrocytes appears to negatively modulate the membrane expression and function of EAAT2, a type of glutamate transporter.
In addition to its effect on the plasma membrane monoamine transporters, methamphetamine inhibits synaptic vesicle function by inhibiting VMAT2, which prevents monoamine uptake into the vesicles and promotes their release. Methamphetamine binds to VMAT2 via the resperine site, in contrast to amphetamine, which appears to bind at the tetrabenazine site. This results in the outflow of monoamines from synaptic vesicles into the cytosol (intracellular fluid) of the presynaptic neuron, and their subsequent release into the synaptic cleft by the phosphorylated transporters. Other transporters that methamphetamine is known to inhibit are SLC22A3 and SLC22A5. SLC22A3 is an extraneuronal monoamine transporter that is present in astrocytes, and SLC22A5 is a high-affinity carnitine transporter.
Methamphetamine is also an agonist of the alpha-2 adrenergic receptors and sigma receptors with a greater affinity for σ1 than σ2, and inhibits monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). Sigma receptor activation by methamphetamine may facilitate its central nervous system stimulant effects and promote neurotoxicity within the brain. Dextromethamphetamine is a stronger psychostimulant, but levomethamphetamine has stronger peripheral effects, a longer half-life, and longer perceived effects among heavy substance users. At high doses, both enantiomers of methamphetamine can induce similar stereotypy and methamphetamine psychosis, but levomethamphetamine has shorter psychodynamic effects.
Pharmacokinetics
The bioavailability of methamphetamine is 67% orally, 79% intranasally, 67 to 90% via inhalation (smoking), and 100% intravenously. Following oral administration, methamphetamine is well-absorbed into the bloodstream, with peak plasma methamphetamine concentrations achieved in approximately 3.13–6.3hours post ingestion. Methamphetamine is also well absorbed following inhalation and following intranasal administration. Because of the high lipophilicity of methamphetamine due to its methyl group, it can readily move through the blood–brain barrier faster than other stimulants, where it is more resistant to degradation by monoamine oxidase. The amphetamine metabolite peaks at 10–24hours. Methamphetamine is excreted by the kidneys, with the rate of excretion into the urine heavily influenced by urinary pH. When taken orally, 30–54% of the dose is excreted in urine as methamphetamine and 10–23% as amphetamine. Following IV doses, about45% is excreted as methamphetamine and 7% as amphetamine. The elimination half-life of methamphetamine varies with a range of 5–30hours, but it is on average 9 to 12hours in most studies. The elimination half-life of methamphetamine does not vary by route of administration, but is subject to substantial interindividual variability.
CYP2D6, dopamine β-hydroxylase, flavin-containing monooxygenase 3, butyrate-CoA ligase, and glycine N-acyltransferase are the enzymes known to metabolize methamphetamine or its metabolites in humans. The primary metabolites are amphetamine and 4-hydroxymethamphetamine; other minor metabolites include: 4-hydroxyamphetamine, 4-hydroxynorephedrine, 4-hydroxyphenylacetone, benzoic acid, hippuric acid, norephedrine, and phenylacetone, the metabolites of amphetamine. Among these metabolites, the active sympathomimetics are amphetamine, 4‑hydroxyamphetamine, 4‑hydroxynorephedrine, 4-hydroxymethamphetamine, and norephedrine. Methamphetamine is a CYP2D6 inhibitor.
The main metabolic pathways involve aromatic para-hydroxylation, aliphatic alpha- and beta-hydroxylation, N-oxidation, N-dealkylation, and deamination. The known metabolic pathways include:
Detection in biological fluids
Methamphetamine and amphetamine are often measured in urine or blood as part of a drug test for sports, employment, poisoning diagnostics, and forensics. Chiral techniques may be employed to help distinguish the source of the drug to determine whether it was obtained illicitly or legally via prescription or prodrug. Chiral separation is needed to assess the possible contribution of levomethamphetamine, which is an active ingredients in some OTC nasal decongestants, toward a positive test result. Dietary zinc supplements can mask the presence of methamphetamine and other drugs in urine.
Methamphetamine can be administered via insufflated, intravenous, oral, rectal, smoked. The route of administration can influence both the onset and intensity of pupil dilation.
The intensity of pupil dilation depends heavily on the dose of Methamphetamine. Effects like pupil dilation are typically reported at common to strong doses. Below is the full dosage chart for Methamphetamine.
Yes. Pupil dilation is a documented physical effect of Methamphetamine. A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to dramatic saucer-like expansion where the dark pupil dominates the iris. This effect is one of the most recognizable signs of psychedelic and stimulant intoxication and directly contributes to light sensitivity, enhanced color perception, and the characteristic "wide-eyed" appearance.
Effects like pupil dilation are typically reported at common doses and above. A common insufflated dose of Methamphetamine is 10–30 mg.
Other substances documented to produce pupil dilation include LSD, MDMA, Amphetamine, Cocaine, Mescaline, and 35 more.
